MTOR and autosomal dominant polycystic kidney disease: Similarly, some previously investigated drugs, for example, mTOR inhibitors and somatostatin analogs, are not widely approved for renoprotection in ADPKD despite interventional trials reporting varying positive effects on TKV [41].